Puma Biotechnology | PBYI - Ebit


Puma Biotechnology reported $-2.2M in EBIT for its fiscal quarter ending in June of 2024.





Ebit Change Date
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Biogen USD 659.6M 157M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Esperion Therapeutics USD -16.03M 11.51M Sep/2024
Exelixis USD 235.91M 20.45M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Glaxosmithkline GBP 3.76B 1.69B Sep/2025
Incyte USD 383.88M 47.44M Dec/2025
MacroGenics USD 20.16M 55.51M Sep/2025
Moderna USD -857M 597M Dec/2025
Novartis USD -9.19B 13.87B Jun/2025
Pfizer USD 4.65B 71M Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
Takeda JPY 257.49B 568.56B Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vanda Pharmaceuticals USD -10.28M 721K Dec/2024
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025